October 21, 2021
Cedilla Therapeutics
Cedilla Therapeutics Unveils Lead Programs for the Conditional Inhibition of TEAD and CDK2, Two High Value and Historically Undruggable Cancer Drivers
October 20, 2021
Voyager Therapeutics
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy At Virtual Congress Of The European Society Of Gene And Cell Therapy
October 15, 2021
Goldfinch Bio
Goldfinch Bio Announces Upcoming Presentations at American Society of Human Genetics (ASHG) 2021 Meeting and American Society of Nephrology’s (ASN) Kidney Week 2021go
October 13, 2021
Rheos Medicines
Rheos Medicines to Present Data at ACR 2021 for MALT1 Inhibitors in Autoimmune and Inflammatory Disease and Announces RHX-317 as First Development Candidate
October 13, 2021
Ambys Medicines
Ambys Medicines announces John Choi is joining as VP of Regulatory Affairs as it initiates IND activities for its lead allogeneic liver cell transplantation program